Mettler-Toledo International Inc. (0K10.L)
USD 991.96
(-4.33%)
USD 991.96
(-4.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.09 Billion USD | 3.11% |
| 2022 | 2.03 Billion USD | 19.53% |
| 2021 | 1.7 Billion USD | 27.11% |
| 2020 | 1.33 Billion USD | 14.28% |
| 2019 | 1.17 Billion USD | 36.82% |
| 2018 | 856.58 Million USD | 3.06% |
| 2017 | 831.16 Million USD | 13.03% |
| 2016 | 735.35 Million USD | 49.85% |
| 2015 | 490.73 Million USD | 33.83% |
| 2014 | 366.69 Million USD | 19.65% |
| 2013 | 306.46 Million USD | 401.34% |
| 2012 | -101.7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.01 Billion USD | -5.17% |
| 2024 Q2 | 1.98 Billion USD | -1.46% |
| 2023 FY | 2.12 Billion USD | 4.51% |
| 2023 Q4 | 2.12 Billion USD | 4.3% |
| 2023 Q1 | 2.03 Billion USD | -0.04% |
| 2023 Q2 | 2.06 Billion USD | 1.74% |
| 2023 Q3 | 2.03 Billion USD | -1.47% |
| 2022 Q1 | 1.75 Billion USD | 3.1% |
| 2022 Q4 | 2.03 Billion USD | 9.59% |
| 2022 FY | 2.03 Billion USD | 19.53% |
| 2022 Q2 | 1.81 Billion USD | 3.61% |
| 2022 Q3 | 1.85 Billion USD | 2.1% |
| 2021 Q3 | 1.5 Billion USD | -0.22% |
| 2021 FY | 1.7 Billion USD | 27.11% |
| 2021 Q1 | 1.5 Billion USD | 14.81% |
| 2021 Q2 | 1.51 Billion USD | 0.39% |
| 2021 Q4 | 1.7 Billion USD | 12.78% |
| 2020 Q3 | 1.07 Billion USD | -0.29% |
| 2020 Q2 | 1.07 Billion USD | -13.87% |
| 2020 Q1 | 1.25 Billion USD | 9.07% |
| 2020 FY | 1.33 Billion USD | 14.28% |
| 2020 Q4 | 1.31 Billion USD | 22.24% |
| 2019 FY | 1.17 Billion USD | 36.82% |
| 2019 Q4 | 1.14 Billion USD | 2.64% |
| 2019 Q3 | 1.11 Billion USD | 3.42% |
| 2019 Q2 | 1.07 Billion USD | 8.33% |
| 2019 Q1 | 996.83 Million USD | 16.37% |
| 2018 Q2 | 889.28 Million USD | -0.6% |
| 2018 Q1 | 894.64 Million USD | 7.64% |
| 2018 FY | 856.58 Million USD | 3.06% |
| 2018 Q4 | 856.6 Million USD | -5.58% |
| 2018 Q3 | 907.19 Million USD | 2.01% |
| 2017 Q2 | 823.05 Million USD | 3.04% |
| 2017 Q4 | 831.16 Million USD | -7.66% |
| 2017 FY | 831.16 Million USD | 13.03% |
| 2017 Q1 | 798.79 Million USD | 8.63% |
| 2017 Q3 | 900.12 Million USD | 9.36% |
| 2016 FY | 735.35 Million USD | 49.85% |
| 2016 Q3 | 701.66 Million USD | 17.03% |
| 2016 Q1 | 588.65 Million USD | 19.95% |
| 2016 Q4 | 735.35 Million USD | 4.8% |
| 2016 Q2 | 599.56 Million USD | 1.85% |
| 2015 Q3 | 499.49 Million USD | 3.62% |
| 2015 FY | 490.73 Million USD | 33.83% |
| 2015 Q4 | 490.73 Million USD | -1.75% |
| 2015 Q2 | 482.05 Million USD | 6.26% |
| 2015 Q1 | 453.67 Million USD | 23.72% |
| 2014 Q1 | 354.73 Million USD | 15.75% |
| 2014 Q2 | 360.05 Million USD | 1.5% |
| 2014 Q3 | 362.25 Million USD | 0.61% |
| 2014 Q4 | 366.69 Million USD | 1.23% |
| 2014 FY | 366.69 Million USD | 19.65% |
| 2013 Q4 | 306.46 Million USD | -2.61% |
| 2013 Q2 | 347.94 Million USD | -1.76% |
| 2013 Q3 | 314.66 Million USD | -9.56% |
| 2013 Q1 | 354.16 Million USD | 448.24% |
| 2013 FY | 306.46 Million USD | 401.34% |
| 2012 FY | -101.7 Million USD | 0.0% |
| 2012 Q4 | -101.7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 2137.826% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 6820.575% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -959.229% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -6479.777% |
| bluebird bio, Inc. | 108.57 Million USD | -1832.341% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 23369.321% |
| Imunon, Inc. | -4.69 Million USD | 44744.395% |
| Editas Medicine, Inc. | -87.11 Million USD | 2508.24% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 83.68% |
| Myriad Genetics, Inc. | 88.1 Million USD | -2281.342% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -1083.284% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 6357.53% |
| Verastem, Inc. | -37.27 Million USD | 5727.882% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 74.524% |
| Waters Corporation | 1.96 Billion USD | -7.015% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 92.183% |
| Biogen Inc. | 6.28 Billion USD | 66.637% |
| Nektar Therapeutics | 210.24 Million USD | -897.889% |
| Perrigo Company plc | 3.32 Billion USD | 36.848% |
| Dynavax Technologies Corporation | 106.63 Million USD | -1867.423% |
| Illumina, Inc. | 1.21 Billion USD | -72.814% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -30008.196% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 1942.127% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -1346.112% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -29091.067% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -453.92% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 29648.761% |
| Evolus, Inc. | 63.7 Million USD | -3193.09% |
| Adicet Bio, Inc. | -142 Million USD | 1577.355% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 5800.364% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 7841.557% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -357.372% |
| FibroGen, Inc. | 56.76 Million USD | -3595.742% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -83.228% |
| OPKO Health, Inc. | 230.68 Million USD | -809.457% |
| Homology Medicines, Inc. | 18.43 Million USD | -11279.086% |
| Geron Corporation | 14.76 Million USD | -14112.872% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -32.336% |
| Exelixis, Inc. | -73.05 Million USD | 2971.953% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 3966.783% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 1489.158% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1983.235% |
| Zoetis Inc. | 4.76 Billion USD | 55.944% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 1149.921% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 20931.715% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 121.936% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 14497.214% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -98.996% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -116.647% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 1649.455% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -51.93% |
| Blueprint Medicines Corporation | 702.83 Million USD | -198.5% |
| Insmed Incorporated | 721.62 Million USD | -190.729% |
| TG Therapeutics, Inc. | 17.86 Million USD | -11645.392% |
| Incyte Corporation | -3.17 Billion USD | 166.076% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -173.957% |